{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,2]],"date-time":"2026-06-02T13:29:32Z","timestamp":1780406972698,"version":"3.54.1"},"reference-count":57,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2020,6,1]],"date-time":"2020-06-01T00:00:00Z","timestamp":1590969600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2020,6,1]],"date-time":"2020-06-01T00:00:00Z","timestamp":1590969600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/100001818","name":"Research to Prevent Blindness","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100001818","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100007491","name":"Donald E. and Delia B. Baxter Foundation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100007491","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100001209","name":"Knights Templar Eye Foundation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100001209","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","theclinics.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinics in Laboratory Medicine"],"published-print":{"date-parts":[[2020,6]]},"DOI":"10.1016\/j.cll.2020.02.007","type":"journal-article","created":{"date-parts":[[2020,5,18]],"date-time":"2020-05-18T16:44:51Z","timestamp":1589820291000},"page":"189-204","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":6,"title":["Precision Therapy for Inherited Retinal Disease"],"prefix":"10.1016","volume":"40","author":[{"given":"Nicole","family":"Koulisis","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aaron","family":"Nagiel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.cll.2020.02.007_bib1","unstructured":"Schachat AP, Wilkinson CP, Hinton DR, et\u00a0al. Ryan's retina. 5th edition. 2013."},{"issue":"11","key":"10.1016\/j.cll.2020.02.007_bib2","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1007\/s11095-018-2514-2","article-title":"Progress in inherited retinal disease drug discovery and development: a foundation's perspective","volume":"35","author":"Yerxa","year":"2018","journal-title":"Pharm Res"},{"issue":"3","key":"10.1016\/j.cll.2020.02.007_bib3","doi-asserted-by":"crossref","first-page":"417","DOI":"10.1097\/IAE.0000000000001341","article-title":"Clinical progress in inherited retinal degenerations: gene therapy clinical trials and advances in genetic sequencing","volume":"37","author":"Hafler","year":"2017","journal-title":"Retina"},{"issue":"9","key":"10.1016\/j.cll.2020.02.007_bib4","doi-asserted-by":"crossref","first-page":"1314","DOI":"10.1016\/j.ophtha.2017.04.008","article-title":"Clinically focused molecular investigation of 1000 consecutive families with inherited retinal disease","volume":"124","author":"Stone","year":"2017","journal-title":"Ophthalmology"},{"issue":"5965","key":"10.1016\/j.cll.2020.02.007_bib5","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1038\/309253a0","article-title":"Close genetic linkage between X-linked retinitis pigmentosa and a restriction fragment length polymorphism identified by recombinant DNA probe L1.28","volume":"309","author":"Bhattacharya","year":"1984","journal-title":"Nature"},{"key":"10.1016\/j.cll.2020.02.007_bib6","series-title":"RetNet: summaries of genes and loci causing retinal diseases","author":"Daiger","year":"2019"},{"key":"10.1016\/j.cll.2020.02.007_bib7","first-page":"1","article-title":"Utility of in\u00a0vitro mutagenesis of RPE65 protein for verification of mutational pathogenicity before gene therapy","author":"Yang","year":"2019","journal-title":"JAMA Ophthalmol"},{"issue":"13","key":"10.1016\/j.cll.2020.02.007_bib8","doi-asserted-by":"crossref","first-page":"6916","DOI":"10.1073\/pnas.94.13.6916","article-title":"Efficient photoreceptor-targeted gene expression in\u00a0vivo by recombinant adeno-associated virus","volume":"94","author":"Flannery","year":"1997","journal-title":"Proc Natl Acad Sci U\u00a0S\u00a0A"},{"issue":"21","key":"10.1016\/j.cll.2020.02.007_bib9","doi-asserted-by":"crossref","first-page":"11382","DOI":"10.1073\/pnas.93.21.11382","article-title":"Efficient transfer, integration, and sustained long-term expression of the transgene in adult rat brains injected with a lentiviral vector","volume":"93","author":"Naldini","year":"1996","journal-title":"Proc Natl Acad Sci U\u00a0S\u00a0A"},{"issue":"19","key":"10.1016\/j.cll.2020.02.007_bib10","doi-asserted-by":"crossref","first-page":"10319","DOI":"10.1073\/pnas.94.19.10319","article-title":"Stable and efficient gene transfer into the retina using an HIV-based lentiviral vector","volume":"94","author":"Miyoshi","year":"1997","journal-title":"Proc Natl Acad Sci U\u00a0S\u00a0A"},{"issue":"26","key":"10.1016\/j.cll.2020.02.007_bib11","doi-asserted-by":"crossref","first-page":"3075","DOI":"10.1093\/hmg\/10.26.3075","article-title":"Exchange of surface proteins impacts on viral vector cellular specificity and transduction characteristics: the retina as a model","volume":"10","author":"Auricchio","year":"2001","journal-title":"Hum Mol Genet"},{"key":"10.1016\/j.cll.2020.02.007_bib12","doi-asserted-by":"crossref","first-page":"261","DOI":"10.3389\/fimmu.2013.00261","article-title":"Immunology of AAV-mediated gene transfer in the eye","volume":"4","author":"Willett","year":"2013","journal-title":"Front Immunol"},{"issue":"11","key":"10.1016\/j.cll.2020.02.007_bib13","doi-asserted-by":"crossref","first-page":"977","DOI":"10.1038\/sj.gt.3302030","article-title":"Immune response following intraocular delivery of recombinant viral vectors","volume":"10","author":"Bennett","year":"2003","journal-title":"Gene Ther"},{"issue":"2","key":"10.1016\/j.cll.2020.02.007_bib14","doi-asserted-by":"crossref","first-page":"206","DOI":"10.1093\/ilar.50.2.206","article-title":"AAV-mediated gene therapy for retinal disorders in large animal models","volume":"50","author":"Stieger","year":"2009","journal-title":"ILAR J"},{"key":"10.1016\/j.cll.2020.02.007_bib15","first-page":"100779","article-title":"Retinal stem cell transplantation: balancing safety and potential","author":"Singh","year":"2019","journal-title":"Prog Retin Eye Res"},{"issue":"Suppl 1","key":"10.1016\/j.cll.2020.02.007_bib16","doi-asserted-by":"crossref","first-page":"S2","DOI":"10.1097\/IAE.0000000000002609","article-title":"Surgical technique for subretinal gene therapy in humans with inherited retinal degeneration","volume":"39","author":"Davis","year":"2019","journal-title":"Retina"},{"issue":"Suppl 1","key":"10.1016\/j.cll.2020.02.007_bib17","doi-asserted-by":"crossref","first-page":"S9","DOI":"10.1097\/IAE.0000000000001646","article-title":"Intraoperative use of microscope-integrated optical coherence tomography for subretinal gene therapy delivery","volume":"39","author":"Gregori","year":"2019","journal-title":"Retina"},{"issue":"12","key":"10.1016\/j.cll.2020.02.007_bib18","doi-asserted-by":"crossref","first-page":"2576","DOI":"10.1242\/dev.092270","article-title":"Stem cells in retinal regeneration: past, present and future","volume":"140","author":"Ramsden","year":"2013","journal-title":"Development"},{"issue":"1","key":"10.1016\/j.cll.2020.02.007_bib19","doi-asserted-by":"crossref","first-page":"92","DOI":"10.1038\/ng0501-92","article-title":"Gene therapy restores vision in a canine model of childhood blindness","volume":"28","author":"Acland","year":"2001","journal-title":"Nat Genet"},{"issue":"10097","key":"10.1016\/j.cll.2020.02.007_bib20","doi-asserted-by":"crossref","first-page":"849","DOI":"10.1016\/S0140-6736(17)31868-8","article-title":"Efficacy and safety of voretigene neparvovec (AAV2-hRPE65v2) in patients with RPE65-mediated inherited retinal dystrophy: a randomised, controlled, open-label, phase 3 trial","volume":"390","author":"Russell","year":"2017","journal-title":"Lancet"},{"issue":"9","key":"10.1016\/j.cll.2020.02.007_bib21","doi-asserted-by":"crossref","first-page":"1273","DOI":"10.1016\/j.ophtha.2019.06.017","article-title":"Efficacy, safety, and durability of voretigene neparvovec-rzyl in RPE65 mutation-associated inherited retinal dystrophy: results of phase 1 and 3 trials","volume":"126","author":"Maguire","year":"2019","journal-title":"Ophthalmology"},{"issue":"Pt 3b","key":"10.1016\/j.cll.2020.02.007_bib22","doi-asserted-by":"crossref","first-page":"553","DOI":"10.1038\/eye.1998.145","article-title":"The cone dystrophies","volume":"12","author":"Simunovic","year":"1998","journal-title":"Eye (Lond)"},{"issue":"3","key":"10.1016\/j.cll.2020.02.007_bib23","doi-asserted-by":"crossref","first-page":"302","DOI":"10.1038\/sj.ejhg.5201269","article-title":"CNGB3 mutations account for 50% of all cases with autosomal recessive achromatopsia","volume":"13","author":"Kohl","year":"2005","journal-title":"Eur J Hum Genet"},{"issue":"4","key":"10.1016\/j.cll.2020.02.007_bib24","doi-asserted-by":"crossref","first-page":"722","DOI":"10.1086\/323613","article-title":"CNGA3 mutations in hereditary cone photoreceptor disorders","volume":"69","author":"Wissinger","year":"2001","journal-title":"Am J Hum Genet"},{"issue":"5093","key":"10.1016\/j.cll.2020.02.007_bib25","doi-asserted-by":"crossref","first-page":"377","DOI":"10.1126\/science.8380507","article-title":"Retinal degeneration in choroideremia: deficiency of rab geranylgeranyl transferase","volume":"259","author":"Seabra","year":"1993","journal-title":"Science"},{"issue":"10","key":"10.1016\/j.cll.2020.02.007_bib26","doi-asserted-by":"crossref","first-page":"1507","DOI":"10.1038\/s41591-018-0185-5","article-title":"Beneficial effects on vision in patients undergoing retinal gene therapy for choroideremia","volume":"24","author":"Xue","year":"2018","journal-title":"Nat Med"},{"key":"10.1016\/j.cll.2020.02.007_bib27","doi-asserted-by":"crossref","first-page":"130","DOI":"10.1016\/j.ajo.2018.06.011","article-title":"Two-year results after AAV2-mediated gene therapy for choroideremia: the alberta experience","volume":"193","author":"Dimopoulos","year":"2018","journal-title":"Am J Ophthalmol"},{"key":"10.1016\/j.cll.2020.02.007_bib28","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1016\/j.ajo.2018.09.012","article-title":"Choroideremia gene therapy phase 2 clinical trial: 24-month results","volume":"197","author":"Lam","year":"2019","journal-title":"Am J Ophthalmol"},{"key":"10.1016\/j.cll.2020.02.007_bib29","doi-asserted-by":"crossref","DOI":"10.1001\/jamaophthalmol.2019.3278","article-title":"Efficacy and safety of retinal gene therapy using adeno-associated virus vector for patients with choroideremia: a randomized clinical trial","author":"Fischer","year":"2019","journal-title":"JAMA Ophthalmol"},{"issue":"1","key":"10.1016\/j.cll.2020.02.007_bib30","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1006\/geno.1997.5164","article-title":"Complete exon-intron structure of the retina-specific ATP binding transporter gene (ABCR) allows the identification of novel mutations underlying Stargardt disease","volume":"48","author":"Gerber","year":"1998","journal-title":"Genomics"},{"issue":"3","key":"10.1016\/j.cll.2020.02.007_bib31","doi-asserted-by":"crossref","first-page":"1392","DOI":"10.1167\/iovs.08-2868","article-title":"Complement activation by bisretinoid constituents of RPE lipofuscin","volume":"50","author":"Zhou","year":"2009","journal-title":"Invest Ophthalmol Vis Sci"},{"issue":"3","key":"10.1016\/j.cll.2020.02.007_bib32","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1080\/21678707.2018.1444476","article-title":"Gene therapy for the treatment of X-linked retinitis pigmentosa","volume":"6","author":"Martinez-Fernandez De La Camara","year":"2018","journal-title":"Expert Opin Orphan Drugs"},{"key":"10.1016\/j.cll.2020.02.007_bib34","unstructured":"Biogen announces agreement to acquire Nightstar therapeutics to establish\u00a0clinical pipeline of gene therapy candidates in Ophthalmology. Accessed November 15, 2019. Available at: https:\/\/investors.biogen.com\/news-releases\/news-release-details\/biogen-announces-agreement-acquire-nightstar-therapeutics."},{"key":"10.1016\/j.cll.2020.02.007_bib35","doi-asserted-by":"crossref","first-page":"2730","DOI":"10.2741\/3409","article-title":"Vision tests in the mouse: functional phenotyping with electroretinography","volume":"14","author":"Tanimoto","year":"2009","journal-title":"Front Biosci (Landmark Ed)"},{"issue":"8","key":"10.1016\/j.cll.2020.02.007_bib36","doi-asserted-by":"crossref","first-page":"1854","DOI":"10.1016\/j.ymthe.2017.05.005","article-title":"Codon-optimized rpgr improves stability and efficacy of AAV8 gene therapy in two mouse models of X-linked retinitis pigmentosa","volume":"25","author":"Fischer","year":"2017","journal-title":"Mol Ther"},{"issue":"1","key":"10.1016\/j.cll.2020.02.007_bib37","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1089\/humc.2013.037","article-title":"Preclinical potency and safety studies of an AAV2-mediated gene therapy vector for the treatment of MERTK associated retinitis pigmentosa","volume":"24","author":"Conlon","year":"2013","journal-title":"Hum Gene Ther Clin Dev"},{"issue":"3","key":"10.1016\/j.cll.2020.02.007_bib38","doi-asserted-by":"crossref","first-page":"327","DOI":"10.1007\/s00439-016-1637-y","article-title":"Treatment of retinitis pigmentosa due to MERTK mutations by ocular subretinal injection of adeno-associated virus gene vector: results of a phase I trial","volume":"135","author":"Ghazi","year":"2016","journal-title":"Hum Genet"},{"issue":"4","key":"10.1016\/j.cll.2020.02.007_bib39","doi-asserted-by":"crossref","first-page":"238","DOI":"10.2174\/138920211795860107","article-title":"Retinitis pigmentosa: genes and disease mechanisms","volume":"12","author":"Ferrari","year":"2011","journal-title":"Curr Genomics"},{"issue":"5","key":"10.1016\/j.cll.2020.02.007_bib40","doi-asserted-by":"crossref","first-page":"867","DOI":"10.1038\/mt.2016.37","article-title":"AAV-mediated gene therapy halts retinal degeneration in PDE6beta-deficient dogs","volume":"24","author":"Pichard","year":"2016","journal-title":"Mol Ther"},{"issue":"6","key":"10.1016\/j.cll.2020.02.007_bib41","doi-asserted-by":"crossref","first-page":"495","DOI":"10.1007\/s00417-002-0485-8","article-title":"Prevalence and geographical distribution of Usher syndrome in Germany","volume":"240","author":"Spandau","year":"2002","journal-title":"Graefes Arch Clin Exp Ophthalmol"},{"key":"10.1016\/j.cll.2020.02.007_bib42","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1007\/978-3-319-95046-4_32","article-title":"Ciliopathy: Usher Syndrome","volume":"1085","author":"Tsang","year":"2018","journal-title":"Adv Exp Med Biol."},{"issue":"7","key":"10.1016\/j.cll.2020.02.007_bib43","first-page":"2286","article-title":"Early findings in a Phase I\/IIa clinical program for Usher syndrome 1B (USH1B; MIM #276900)","volume":"56","author":"Weleber","year":"2015","journal-title":"Invest Ophthalmol Vis Sci"},{"issue":"1","key":"10.1016\/j.cll.2020.02.007_bib44","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1016\/j.oret.2018.08.006","article-title":"The natural history of congenital X-linked retinoschisis and conversion between phenotypes over time","volume":"3","author":"Wood","year":"2019","journal-title":"Ophthalmol Retina"},{"issue":"7","key":"10.1016\/j.cll.2020.02.007_bib45","doi-asserted-by":"crossref","first-page":"2891","DOI":"10.1172\/JCI81380","article-title":"Synaptic pathology and therapeutic repair in adult retinoschisis mouse by AAV-RS1 transfer","volume":"125","author":"Ou","year":"2015","journal-title":"J\u00a0Clin Invest"},{"issue":"9","key":"10.1016\/j.cll.2020.02.007_bib46","doi-asserted-by":"crossref","first-page":"2282","DOI":"10.1016\/j.ymthe.2018.05.025","article-title":"Retinal AAV8-RS1 gene therapy for X-linked retinoschisis: initial findings from a phase I\/IIa trial by intravitreal delivery","volume":"26","author":"Cukras","year":"2018","journal-title":"Mol Ther"},{"issue":"6121","key":"10.1016\/j.cll.2020.02.007_bib48","doi-asserted-by":"crossref","first-page":"819","DOI":"10.1126\/science.1231143","article-title":"Multiplex genome engineering using CRISPR\/Cas systems","volume":"339","author":"Cong","year":"2013","journal-title":"Science"},{"issue":"9","key":"10.1016\/j.cll.2020.02.007_bib49","doi-asserted-by":"crossref","first-page":"1999","DOI":"10.1016\/j.ymthe.2017.05.015","article-title":"Using CRISPR-Cas9 to generate gene-corrected autologous iPSCs for the treatment of inherited retinal degeneration","volume":"25","author":"Burnight","year":"2017","journal-title":"Mol Ther"},{"issue":"2","key":"10.1016\/j.cll.2020.02.007_bib50","doi-asserted-by":"crossref","first-page":"331","DOI":"10.1016\/j.ymthe.2016.12.006","article-title":"CRISPR\/Cas9-mediated genome editing as a therapeutic approach for leber congenital amaurosis 10","volume":"25","author":"Ruan","year":"2017","journal-title":"Mol Ther"},{"issue":"2","key":"10.1016\/j.cll.2020.02.007_bib52","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1038\/s41591-018-0327-9","article-title":"Development of a gene-editing approach to restore vision loss in Leber congenital amaurosis type 10","volume":"25","author":"Maeder","year":"2019","journal-title":"Nat Med"},{"issue":"6","key":"10.1016\/j.cll.2020.02.007_bib53","doi-asserted-by":"crossref","first-page":"2177","DOI":"10.1172\/JCI120429","article-title":"Gene therapy and genome surgery in the retina","volume":"128","author":"DiCarlo","year":"2018","journal-title":"J\u00a0Clin Invest"},{"key":"10.1016\/j.cll.2020.02.007_bib54","doi-asserted-by":"crossref","first-page":"517","DOI":"10.1007\/978-3-319-17121-0_69","article-title":"Antisense oligonucleotide therapy for inherited retinal dystrophies","volume":"854","author":"Gerard","year":"2016","journal-title":"Adv Exp Med Biol"},{"key":"10.1016\/j.cll.2020.02.007_bib55","doi-asserted-by":"crossref","first-page":"e14","DOI":"10.1038\/mtna.2012.3","article-title":"Antisense oligonucleotide (AON)-based therapy for leber congenital amaurosis caused by a frequent mutation in CEP290","volume":"1","author":"Collin","year":"2012","journal-title":"Mol Ther Nucleic Acids"},{"issue":"6","key":"10.1016\/j.cll.2020.02.007_bib56","doi-asserted-by":"crossref","first-page":"E517","DOI":"10.1073\/pnas.1218933110","article-title":"Human retinal gene therapy for Leber congenital amaurosis shows advancing retinal degeneration despite enduring visual improvement","volume":"110","author":"Cideciyan","year":"2013","journal-title":"Proc Natl Acad Sci U\u00a0S\u00a0A"},{"issue":"5","key":"10.1016\/j.cll.2020.02.007_bib57","doi-asserted-by":"crossref","first-page":"2710","DOI":"10.1073\/pnas.1913179117","article-title":"Worldwide carrier frequency and genetic prevalence of autosomal recessive inherited retinal diseases","volume":"117","author":"Hanany","year":"2020","journal-title":"Proc Natl Acad Sci U\u00a0S\u00a0A"},{"key":"10.1016\/j.cll.2020.02.007_bib58","article-title":"Diagnostic yield of panel-based genetic testing in syndromic inherited retinal disease","author":"Jiman","year":"2019","journal-title":"Eur J Hum Genet"},{"issue":"6","key":"10.1016\/j.cll.2020.02.007_bib59","doi-asserted-by":"crossref","first-page":"888","DOI":"10.1016\/j.ophtha.2018.12.050","article-title":"The oculome panel test: next-generation sequencing to diagnose a diverse range of genetic developmental eye disorders","volume":"126","author":"Patel","year":"2019","journal-title":"Ophthalmology"},{"issue":"9701","key":"10.1016\/j.cll.2020.02.007_bib60","doi-asserted-by":"crossref","first-page":"1597","DOI":"10.1016\/S0140-6736(09)61836-5","article-title":"Age-dependent effects of RPE65 gene therapy for Leber's congenital amaurosis: a phase 1 dose-escalation trial","volume":"374","author":"Maguire","year":"2009","journal-title":"Lancet"}],"container-title":["Clinics in Laboratory Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0272271220300196?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0272271220300196?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,2]],"date-time":"2025-10-02T23:56:41Z","timestamp":1759449401000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0272271220300196"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,6]]},"references-count":57,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2020,6]]}},"alternative-id":["S0272271220300196"],"URL":"https:\/\/doi.org\/10.1016\/j.cll.2020.02.007","relation":{},"ISSN":["0272-2712"],"issn-type":[{"value":"0272-2712","type":"print"}],"subject":[],"published":{"date-parts":[[2020,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Precision Therapy for Inherited Retinal Disease","name":"articletitle","label":"Article Title"},{"value":"Clinics in Laboratory Medicine","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.cll.2020.02.007","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2020 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}